Huy G Vuong

List of Publications by Year
in descending order

55 papers	1,321 citations	304743 22 h-index	395702 33 g-index
62 all docs	62 docs citations	62 times ranked	1497 citing authors

#	Article	IF	Citations
1	Absence of Survival Improvement for Patients with Esthesioneuroblastoma Over the Past 2 Decades: A Population-Based Study. World Neurosurgery, 2022, 157, e245-e253.	1.3	1
2	The differences in distant metastatic patterns and their corresponding survival between thyroid cancer subtypes. Head and Neck, 2022, 44, 926-932.	2.0	23
3	The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas. Cancer, 2022, 128, 1907-1912.	4.1	16
4	Chondrosarcoma and Chordoma of the Skull Base and Spine: Implication of Tumor Location on Patient Survival. World Neurosurgery, 2022, 162, e635-e639.	1.3	5
5	Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas. Frontiers in Oncology, 2022, 12, 858148.	2.8	9
6	Risk stratification of H3 K27Mâ€“mutant diffuse midline gliomas based on anatomical locations: an integrated systematic review of individual participant data. Journal of Neurosurgery: Pediatrics, 2022, 30, 99-106.	1.3	5
7	Clinical detection of â€œextremely lowâ€•riskâ€•follicular thyroid carcinoma: A populationâ€based study of 7304 patients. Laryngoscope Investigative Otolaryngology, 2022, 7, 1235-1242.	1.5	2
8	Primary versus secondary gliosarcoma: a systematic review and meta-analysis. Journal of Neuro-Oncology, 2022, 159, 195-200.	2.9	4
9	Impact of Molecular Testing on the Management of Indeterminate Thyroid Nodules Among Western and Asian Countries: a Systematic Review and Meta-analysis. Endocrine Pathology, 2021, 32, 269-279.	9.0	17
10	Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A metaâ€analysis. Cancer Cytopathology, 2021, 129, 182-189.	2.4	35
11	Risk factors for tumor recurrence and progression of spindle cell oncocytoma of the pituitary gland: a systematic review and pooled analysis. Pituitary, 2021, 24, 429-437.	2.9	5
12	Application of the Bethesda System for Reporting Thyroid Cytopathology in the Pediatric Population. American Journal of Clinical Pathology, 2021, 155, 680-689.	0.7	15
13	Incidence, risk factors, and prognosis of meningiomas with distant metastases at presentation. Neuro-Oncology Advances, 2021, 3, vdab084.	0.7	4
14	Consolidating the Hyams grading system in esthesioneuroblastoma â€“ an individual participant data meta-analysis. Journal of Neuro-Oncology, 2021, 153, 15-22.	2.9	6
15	The Use of the Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: A Meta-Analysis. Thyroid, 2021, 31, 1203-1211.	4.5	37
16	Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data metaâ€analysis. Cancer Medicine, 2021, 10, 4415-4423.	2.8	27
17	Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 431-438.	0.4	14
18	The Incidence of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Meta-Analysis Assessing Worldwide Impact of the Reclassification. Thyroid, 2021, 31, 1502-1513.	4.5	16

#	Article	IF	Citations
19	Malignant thyroid teratoma: an integrated analysis of case series/case reports. Endocrine-Related Cancer, 2021, 28, 495-503.	3.1	4
20	Response to Cherella et al. re: â€œThe Use of the Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: A Meta-Analysisâ€• Thyroid, 2021, 31, 1442-1444.	4.5	5
21	Primary Versus Secondary Anaplastic Thyroid Carcinoma: Perspectives from Multi-institutional and Population-Level Data. Endocrine Pathology, 2021, 32, 489-500.	9.0	6
22	H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. Journal of Neuro-Oncology, 2021, 155, 225-234.	2.9	20
23	Incidence, Prognostic Factors, and Survival Trend in Pineal Gland Tumors: A Population-Based Analysis. Frontiers in Oncology, 2021, 11, 780173.	2.8	9
24	Longâ€term outcomes of primary cardiac malignant tumors: Difference between African American and Caucasian population. Cancer Medicine, 2021, 10, 8838-8845.	2.8	4
25	Differences in surgical resection rate and risk of malignancy in thyroid cytopathology practice between Western and Asian countries: A systematic review and metaâ€analysis. Cancer Cytopathology, 2020, 128, 238-249.	2.4	93
26	Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations. Endocrine Pathology, 2020, 31, 359-366.	9.0	15
27	The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. BMC Cancer, 2020, 20, 897.	2.6	26
28	Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis. Targeted Oncology, 2020, 15, 589-598.	3.6	17
29	The diversities in thyroid cytopathology practices among Asian countries using the Bethesda system for reporting thyroid cytopathology. Gland Surgery, 2020, 9, 1735-1746.	1.1	12
30	Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review. Gland Surgery, 2020, 9, 1813-1826.	1.1	0
31	Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review. Gland Surgery, 2020, 9, 1813-1826.	1.1	6
32	Assessment of peritoneal elastic laminal invasion improves survival stratification of pT3 and pT4a colorectal cancer: a meta-analysis. Journal of Clinical Pathology, 2019, 72, 736-740.	2.0	5
33	Clinical Impact of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features on the Risk of Malignancy in the Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis of 14,153 Resected Thyroid Nodules. Endocrine Practice, 2019, 25, 491-502.	2.1	29
34	Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and metaâ€analysis. Head and Neck, 2019, 41, 2823-2829.	2.0	5
35	Prognostic significance of genetic biomarkers in isocitrate dehydrogenaseâ€wildâ€type lowerâ€grade glioma: the need to further stratify this tumor entity â€“ a metaâ€analysis. European Journal of Neurology, 2019, 26, 379-387.	3.3	18
36	BRAF Mutation is Associated with an Improved Survival in Gliomaâ€”a Systematic Review and Meta-analysis. Molecular Neurobiology, 2018, 55, 3718-3724.	4.0	31

#	Article	IF	Citations
37	Prognostic importance of solid variant papillary thyroid carcinoma: A systematic review and metaâ€analysis. Head and Neck, 2018, 40, 1588-1597.	2.0	36
38	Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis. Endocrine-Related Cancer, 2018, 25, 633-641.	3.1	39
39	Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Metaâ€analysis. World Journal of Surgery, 2018, 42, 1005-1017.	1.6	40
40	Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis. Endocrine Connections, 2018, 7, R286-R293.	1.9	26
41	High expression of <scp>CD</scp>10 in anaplastic thyroid carcinomas. Histopathology, 2018, 73, 492-499.	2.9	6
42	Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer â€“ A systematic review and meta-analysis. Lung Cancer, 2018, 123, 76-82.	2.0	88
43	A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocrine Connections, 2017, 6, R8-R17.	1.9	68
44	Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. European Journal of Endocrinology, 2017, 176, 433-441.	3.7	56
45	Paediatric follicular thyroid carcinoma â€“ indolent cancer with low prevalence of <scp>RAS</scp> mutations and absence of <scp>PAX</scp>8â€“<scp>PPARG</scp> fusion in a Japanese population. Histopathology, 2017, 71, 760-768.	2.9	24
46	Prognostic impact of vascular invasion in differentiated thyroid carcinoma: a systematic review and meta-analysis. European Journal of Endocrinology, 2017, 177, 207-216.	3.7	30
47	TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroupsâ€"A meta-analysis of aggregate data. Critical Reviews in Oncology/Hematology, 2017, 120, 1-9.	4.4	44
48	Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutationsâ€"a meta-analysis. Tumor Biology, 2017, 39, 101042831771391.	1.8	38
49	Prognostic implication of <scp>BRAF</scp> and <scp>TERT</scp> promoter mutation combination in papillary thyroid carcinomaâ€"A metaâ€analysis. Clinical Endocrinology, 2017, 87, 411-417.	2.4	99
50	Chromophobe renal cell carcinoma-like thyroid carcinoma: A novel clinicopathologic entity possibly associated with tuberous sclerosis complex. Endocrine Journal, 2017, 64, 843-850.	1.6	8
51	The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: a systematic review. Oncotarget, 2017, 8, 10637-10649.	1.8	67
52	Genetic alterations of differentiated thyroid carcinoma in iodineâ€rich and iodineâ€deficient countries. Cancer Medicine, 2016, 5, 1883-1889.	2.8	45
53	Immunohistochemical detection of NRASQ61R protein in follicular-patterned thyroid tumors. Human Pathology, 2016, 53, 51-57.	2.0	26
54	Spindle cell oncocytoma of adenohypophysis: Report of a case and immunohistochemical review of literature. Pathology Research and Practice, 2016, 212, 222-225.	2.3	23

#	Article	IF	Citations
55	The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. Journal of Neuro-Oncology, 0, , .	2.9	12